Chemoradiation followed by adjuvant durvalumab in <scp>stage III non–small</scp> cell lung cancer: <scp>Real‐world</scp> comparison of treatment outcomes to historical controls treated with chemoradiation alone-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Chemoradiation followed by adjuvant durvalumab in stage III non–small cell lung cancer: Real‐world comparison of treatment outcomes to historical controls treated with chemoradiation alone

Published:2022-05-11 Issue:12 Volume:13 Page:1763-1771
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Saad Akram¹²^ORCID,Goldstein Jeffrey³,Appel Sarit¹²,Daher Sameh¹²,Urban Damien¹²,Onn Amir¹²,Gantz‐Sorotsky Hadas¹²,Lobachov Anastasiya¹,Gottfried Teodor¹,Spieler Benjamin⁴,Bar Jair¹²

Affiliation:

1. Oncology Institute, Sheba Medical Center Tel‐Hashomer Israel

2. Sackler Faculty of Medicine, Tel‐Aviv University Tel‐Aviv Israel

3. Department of Radiation Oncology Tel‐Aviv Sourasky Medical Center Tel‐Aviv Israel

4. Department of Radiation Oncology University of Miami School of Medicine Miami Florida USA

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14452

Reference24 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

3. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

4. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer

5. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non–Small-Cell Lung Cancer: KCSG-LU05-04

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The future of cancer treatment: combining radiotherapy with immunotherapy;Frontiers in Molecular Biosciences;2024-07-09

2. Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;International Journal of Radiation Oncology*Biology*Physics;2024-07

3. Integrating Durvalumab with Neoadjuvant Chemoradiation and Surgery in Patients with Borderline Resectable Stage III Non-Small Cell Lung Cancer: A Retrospective Case Series;2024-02-22

4. Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study;Anticancer Research;2024-02

5. Effect of Sequence of Radiotherapy Combined With Immunotherapy on the Incidence of Pneumonitis in Patients With Lung Cancer: A Systematic Review and Network Meta-Analysis;Clinical Lung Cancer;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3